Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)

BACKGROUND: The use of hydroxychloroquine or chloroquine (HCQ/CQ) as monotherapy or combined with azithromycin for the treatment of coronavirus disease 2019 (COVID-19) may increase the risk of serious cardiovascular adverse events (SCAEs). OBJECTIVE: Our objective was to describe and evaluate the ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ying, Zhang, Jingru, Zheng, Kai, Thai, Sydney, Simpson, Ross J., Kinlaw, Alan C., Xu, Yang, Wei, Jingkai, Cui, Xiangli, Buse, John B, Stürmer, Til, Wang, Tiansheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985751/
https://www.ncbi.nlm.nih.gov/pubmed/35386046
http://dx.doi.org/10.1007/s40801-022-00300-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985751/
https://www.ncbi.nlm.nih.gov/pubmed/35386046
http://dx.doi.org/10.1007/s40801-022-00300-y

Ejemplares similares